# Understanding the impact that tumor representative oxygen tension has on phosphotyrosine-dependent signaling networks in solid tumors

> **NIH NIH K00** · UT SOUTHWESTERN MEDICAL CENTER · 2024 · $92,113

## Abstract

PROJECT SUMMARY/ ABSTRACT
The perturbation of phospho-tyrosine mediated signaling networks is an essential occurrence during the
multistep process of tumor development and progression. As a result, the components of these phospho-tyrosine
signaling networks, especially tyrosine kinases, have been shown to be a key reservoir of actionable molecular
targets for the treatment of cancer. In recent years, it has been revealed that the tumor microenvironment plays
a critical role in modulating the signaling pathways that govern tumor progression and metastasis. The features
of a tumor's microenvironment have been shown to produce unique sensitivities and resistances to different
treatment modalities. One major aspect of the tumor microenvironment which is often overlooked in preclinical
studies is oxygen tension. This proposal seeks to understand the impact that oxygen tension has on
phosphotyrosine-dependent signaling networks in solid tumors, and how the resultant vulnerabilities can be
targeted to improve patient outcome. In Aim 1.1 (prior studies), we sought to identify alterations in signaling
networks that occur when lung cancer cells colonize the brain, a hypoxic environment. We showed that brain-
metastatic lung cancer cells elevate and have an increased dependence on a non-canonical HSF1-E2F
transcriptional program for survival. Importantly, we identified that this transcriptional program is targetable
through treatment with allosteric ABL2 tyrosine kinase inhibitors. In Aim 1.2 (proposed studies), using a small
molecule screen, I have identified previously unrecognized modulators of the cellular response to hypoxia, a
tumor microenvironment feature associated with increased metastasis and lower overall survival in patients with
solid tumors. The top uncharacterized hit was the FDA-approved ABL1/2 tyrosine kinase inhibitor Dasatinib and
my preliminary investigation has shown that the ABL kinases are critical regulators of HIF-1α protein stability. I
will continue mechanistic investigation of the ABL- HIF-1α axis in vitro and in vivo. Finally, in Aim 2 (post-doctoral
studies), I will focus on understanding the impact that tumor representative- oxygen tension has on protein
tyrosine phosphatase activity. Extensive investigation has demonstrated that tumor hypoxia induces activation
of phospho-tyrosine signaling networks, but current work has almost exclusively focused on the role of tyrosine
kinases. I show that hypoxia induces inhibitory oxidation of protein tyrosine phosphatases (PTPs). Using mass-
spectrometry based approaches, I will identify the oxidized- PTP landscape (ox-PTPome) of tumor samples and
cancer cells at oxygen levels observed in tumors. Further, since PTPs restrain cellular signaling, I will employ
high-throughput drug screening technologies in vitro to identify emergent sensitivities due to the loss of PTP
activity that would not have been captured in the numerous normoxically (tumor-unrepresentative oxygen level)
performed s...

## Key facts

- **NIH application ID:** 10857205
- **Project number:** 5K00CA264162-04
- **Recipient organization:** UT SOUTHWESTERN MEDICAL CENTER
- **Principal Investigator:** Benjamin Jacob Mayro
- **Activity code:** K00 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $92,113
- **Award type:** 5
- **Project period:** 2021-09-01 → 2027-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10857205

## Citation

> US National Institutes of Health, RePORTER application 10857205, Understanding the impact that tumor representative oxygen tension has on phosphotyrosine-dependent signaling networks in solid tumors (5K00CA264162-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10857205. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
